#1 Clinical Trials Search in Europe

Relatlimab

Relatlimab is an innovative immunotherapy drug being studied in various clinical trials for its potential to treat different types of cancer. This article explores the ongoing research into Relatlimab, focusing on its use in combination with other drugs, particularly Nivolumab, in treating melanoma, colorectal cancer, hepatocellular carcinoma, and lymphoma. We’ll examine the drug’s mechanism, potential benefits, and current findings from clinical trials.

Table of Contents

What is Relatlimab?

Relatlimab is a new type of immunotherapy drug that is currently being studied for the treatment of various types of cancer[1]. It is also known by its alternative names BMS-986016 and Anti-LAG-3[7]. Immunotherapy is a type of cancer treatment that helps your body’s own immune system fight cancer cells.

How Does Relatlimab Work?

Relatlimab works by targeting a protein called LAG-3 (Lymphocyte-Activation Gene 3) that is found on certain immune cells[2]. LAG-3 can sometimes prevent immune cells from effectively fighting cancer. By blocking LAG-3, Relatlimab helps to “take the brakes off” the immune system, allowing it to better recognize and attack cancer cells.

What Conditions Does Relatlimab Treat?

Relatlimab is being studied for the treatment of several types of cancer, including:

  • Melanoma: A type of skin cancer[2]
  • Colorectal cancer: Cancer of the colon or rectum[3]
  • Hepatocellular carcinoma: The most common type of liver cancer[7]
  • Lymphoma: Cancer that begins in cells of the lymph system[8]
  • Uveal melanoma: A rare type of eye cancer[6]

Combination Therapy with Nivolumab

In many clinical trials, Relatlimab is being studied in combination with another immunotherapy drug called Nivolumab (also known as Opdivo)[2]. Nivolumab works by targeting a different protein called PD-1. The combination of Relatlimab and Nivolumab is thought to potentially enhance the immune system’s ability to fight cancer more effectively than either drug alone.

Current Clinical Trials

Relatlimab is currently being studied in several clinical trials to determine its safety and effectiveness. Some of these trials include:

  • A study for patients with advanced melanoma who have not received prior immunotherapy[2]
  • A trial for patients with colorectal cancer that is resistant to other treatments[3]
  • A study for patients with liver cancer who may be eligible for surgery[7]
  • A trial for children and young adults with certain types of lymphoma[8]

Potential Side Effects

As with all medications, Relatlimab may cause side effects. In clinical trials, researchers are carefully monitoring patients for any adverse reactions[8]. Common side effects of immunotherapy drugs can include fatigue, skin rashes, and diarrhea. More serious side effects are possible but less common. It’s important to discuss potential risks and benefits with your healthcare provider.

Future Prospects

Relatlimab shows promise in the field of cancer immunotherapy. Researchers are excited about its potential to help patients with various types of cancer, especially when combined with other immunotherapy drugs like Nivolumab[2]. However, it’s important to remember that Relatlimab is still in the research phase and is not yet approved for general use outside of clinical trials.

If you’re interested in learning more about Relatlimab or participating in a clinical trial, talk to your oncologist or healthcare provider. They can provide more information and help determine if this treatment might be appropriate for your specific situation.

Aspect Details
Drug Name Relatlimab (also known as BMS-986016)
Drug Type Immunotherapy, targeting LAG-3 protein
Common Combination Often used with Nivolumab (anti-PD-1 drug)
Cancers Studied Melanoma, Colorectal Cancer, Hepatocellular Carcinoma, Lymphoma
Administration Intravenous, typically every 4 weeks
Key Outcomes Measured Objective Response Rate, Progression-Free Survival, Overall Survival
Safety Monitoring Adverse Events, Serious Adverse Events, Laboratory Abnormalities
Treatment Duration Varies by trial, often up to 2 years or until disease progression

FAQ

  • What is Relatlimab and how does it work? Relatlimab is an immunotherapy drug that targets LAG-3, a protein found on immune cells. It works by blocking LAG-3, which helps to activate the immune system to fight cancer cells more effectively.
  • In which types of cancers is Relatlimab being studied? Relatlimab is being studied in various cancers including melanoma (including uveal melanoma), colorectal cancer, hepatocellular carcinoma (liver cancer), and lymphoma (both Hodgkin and non-Hodgkin).
  • How is Relatlimab typically administered in clinical trials? In most trials, Relatlimab is administered intravenously (through a vein) every 4 weeks, often in combination with another immunotherapy drug called Nivolumab.
  • What are some potential side effects of Relatlimab? While specific side effects vary between trials, common side effects of immunotherapy drugs like Relatlimab can include fatigue, skin reactions, and immune-related adverse events. The trials are closely monitoring for any treatment-related toxicities.
  • How long do patients typically receive Relatlimab in clinical trials? The duration of treatment varies between trials, but many studies administer Relatlimab for up to 2 years or until disease progression or intolerable side effects occur.

Ongoing Clinical Trials on Relatlimab

  • Study on the Safety and Effects of XL092 with Nivolumab, Ipilimumab, and Relatlimab for Patients with Advanced Solid Tumors

    Not recruiting

    1 1 1
    Investigated drugs:
    Austria Belgium France Germany Italy Poland +1

  • Study Comparing Relatlimab and Nivolumab Combination vs. Nivolumab Alone for Patients with Advanced Melanoma

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium Denmark Finland France Germany +7

  • Study of Nivolumab, Relatlimab and Bevacizumab combination for patients with untreated advanced or metastatic liver cancer (hepatocellular carcinoma)

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy Poland Spain

  • Study of Relatlimab and Nivolumab with Chemotherapy for Patients with Stage IV or Recurrent Non-Small Cell Lung Cancer

    Not recruiting

    1 1 1
    Investigated drugs:
    Belgium France Germany Ireland Italy The Netherlands +3

  • Study of Nivolumab and Relatlimab for Patients with Resectable Non-Small Cell Lung Cancer

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Germany The Netherlands

  • Study Comparing Relatlimab-Nivolumab Combination with Regorafenib or Trifluridine-Tipiracil for Patients with Advanced Metastatic Colorectal Cancer

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia France Germany Italy +4

  • Study on Patient Preference for Nivolumab and Relatlimab Administration Methods in Melanoma Patients

    Not recruiting

    1 1 1
    Investigated drugs:
    Greece Italy Spain

  • Study of Relatlimab and Nivolumab for Patients with Advanced Liver Cancer Who Have Not Received Immunotherapy After Tyrosine Kinase Inhibitor Treatment

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia France Poland Romania Spain

  • Study of Relatlimab and Nivolumab for Children and Young Adults with Recurrent or Refractory Hodgkin and Non-Hodgkin Lymphoma

    Not recruiting

    1 1 1
    Investigated drugs:
    France Italy The Netherlands Spain

Glossary

  • Immunotherapy: A type of cancer treatment that helps your immune system fight cancer.
  • LAG-3: Lymphocyte-activation gene 3, a protein found on immune cells that Relatlimab targets.
  • Nivolumab: An immunotherapy drug often used in combination with Relatlimab that targets a different protein called PD-1.
  • Intravenous (IV): Administration of a drug directly into a vein.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it getting worse.
  • Overall Survival (OS): The length of time from the start of treatment that patients are still alive.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease associated with the use of a medical treatment.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a set of rules used to measure how well a cancer patient responds to treatment.
  • Metastatic: Cancer that has spread from its original site to other parts of the body.

References

  1. https://clinicaltrials.gov/study/NCT03607890
  2. https://clinicaltrials.gov/study/NCT03743766
  3. https://clinicaltrials.gov/study/NCT03642067
  4. https://clinicaltrials.gov/study/NCT05170659
  5. https://clinicaltrials.gov/study/NCT05704647
  6. https://clinicaltrials.gov/study/NCT04552223
  7. https://clinicaltrials.gov/study/NCT04658147
  8. https://clinicaltrials.gov/study/NCT05255601